Literature DB >> 32119

The incretin concept today.

W Creutzfeldt.   

Abstract

1. The insulinogenic factor of the gastrointestinal mucosa named "incretin" is only one part of the complex enteroinsular axis. --2. Of the chemically defined gastrointestinal hormones GIP is the strongest incretin candidate. --3. Because of the dual function of GIP as gastrone and insulinotropic substance several safeguards against GIP-mediated insulin hypoglycaemia exist. --4. No pathological condition has yet been found which is causally related to hyper- or hyposecretion of GIP. However, an exaggerated GIP response (usually secondary to the disease) may participate in the pathogenesis of hyperinsulinaemia of patients with obesity and duodenal ulcer. --5. The injection of GIP antibodies only partially abolishes the incretin effect. Therefore, GIP, although important, is not the only incretin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 32119     DOI: 10.1007/bf01225454

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  55 in total

Review 1.  Identification and actions of gastric inhibitory polypeptide.

Authors:  J C Brown; J R Dryburgh; S A Ross; J Dupré
Journal:  Recent Prog Horm Res       Date:  1975

2.  The insulinotropic effect of endogenous gastric inhibitory polypeptide in normal subjects.

Authors:  S E Crockett; S Cataland; J M Falko; E L Mazzaferri
Journal:  J Clin Endocrinol Metab       Date:  1976-06       Impact factor: 5.958

3.  Effects of the gastric inhibitory polypeptide present in impure pancreozymin-cholecystokinin on plasma insulin and glucagon in the rat.

Authors:  A Rabinovitch; J Dupré
Journal:  Endocrinology       Date:  1974-04       Impact factor: 4.736

4.  Glucose turnover and insulin secretion in dogs with pancreatic allografts.

Authors:  A Jakob; F Largiadèr; E R Froesch
Journal:  Diabetologia       Date:  1970-08       Impact factor: 10.122

5.  Effect of atropine on glucose-stimulated gastric inhibitory polypeptide.

Authors:  J N Larrimer; E L Mazzaferri; S Cataland; H S Mekhjian
Journal:  Diabetes       Date:  1978-06       Impact factor: 9.461

6.  Stimulation of gastric inhibitory polypeptide in normal and duodenal ulcer patients.

Authors:  S Cataland; T M O'Dorisio; R Brooks; H S Mekhjian
Journal:  Gastroenterology       Date:  1977-07       Impact factor: 22.682

7.  Carbohydrate metabolism in duodenal ulcer patients.

Authors:  K D Buchanan; M T McKiddie; A C Lindsay; W G Manderson
Journal:  Gut       Date:  1967-08       Impact factor: 23.059

8.  Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.

Authors:  D K Andersen; D Elahi; J C Brown; J D Tobin; R Andres
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Innervation of the pancreas by vasoactive intestinal polypeptide (VIP) immunoreactive nerves.

Authors:  L I Larsson; J Fahrenkrug; J J Holst; O B Schaffalitzky de Muckadell
Journal:  Life Sci       Date:  1978-03       Impact factor: 5.037

10.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.

Authors:  M J Perley; D M Kipnis
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

View more
  144 in total

Review 1.  Promising new approaches to the management of obesity.

Authors:  I L Mertens; L F Van Gaal
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

2.  Diabetologia--25 years.

Authors:  C Hellerström
Journal:  Diabetologia       Date:  1990-08       Impact factor: 10.122

3.  The preliminary clinical experience with laparoscopic duodenojejunal bypass for treatment of type 2 diabetes mellitus in non-morbidly obese patients: the 1-year result in a single institute.

Authors:  Kwang Yeol Paik; Wook Kim; Ki-Ho Song; Hyuk Sang Kwon; Mee Kyoung Kim; Eungkook Kim
Journal:  Surg Endosc       Date:  2012-06-08       Impact factor: 4.584

Review 4.  [GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].

Authors:  Björn A Menge; Juris J Meier; Wolfgang E Schmidt
Journal:  Med Klin (Munich)       Date:  2010-03

5.  Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.

Authors:  Omprakash Tanwar; Girdhar Singh Deora; Lalima Tanwar; Gautam Kumar; Sridhara Janardhan; Mumtaz Alam; Mymoona Akhter
Journal:  J Mol Model       Date:  2014-04-01       Impact factor: 1.810

6.  Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance.

Authors:  Georgios C Boronikolos; Björn A Menge; Nina Schenker; Thomas G K Breuer; Jan-Michel Otte; Sascha Heckermann; Freimut Schliess; Juris J Meier
Journal:  Diabetologia       Date:  2015-03-01       Impact factor: 10.122

7.  Adrenergic modulation of gastric inhibitory polypeptide secretion in man.

Authors:  M Salera; R Ebert; P Giacomoni; L Pironi; S Venturi; R Corinaldesi; M Miglioli; L Barbara
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

8.  Identification of an alpha-adrenoceptor binding inhibitor: possible implications in diabetes mellitus.

Authors:  M D Wider; J C Dunbar; P M Duhaime
Journal:  Acta Diabetol Lat       Date:  1985 Jul-Sep

9.  Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1.

Authors:  G G Holz; C A Leech; J F Habener
Journal:  J Biol Chem       Date:  1995-07-28       Impact factor: 5.157

Review 10.  Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Authors:  Baptist Gallwitz
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.